OTC and Rx single ingredient and fixed dose combination drugs containing paracetamol marketed in the EU are set to carry an updated warning about the risk of a serious blood and fluid abnormality.
Following a review of all the available evidence of a link between paracetamol use and high anion gap metabolic acidosis (HAGMA) due to pyroglutamic acidosis, the European Medicines Agency’s Pharmacovigilance...